| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 121 | 2022 | 258 | 28.210 |
Why?
|
| Surveys and Questionnaires | 88 | 2022 | 1150 | 13.970 |
Why?
|
| Rheumatic Diseases | 35 | 2019 | 53 | 10.790 |
Why?
|
| Antirheumatic Agents | 47 | 2018 | 85 | 10.480 |
Why?
|
| Health Status Indicators | 33 | 2022 | 70 | 9.520 |
Why?
|
| Severity of Illness Index | 81 | 2022 | 892 | 9.390 |
Why?
|
| Rheumatology | 36 | 2022 | 84 | 9.390 |
Why?
|
| Health Status | 36 | 2016 | 219 | 6.780 |
Why?
|
| Disability Evaluation | 31 | 2022 | 266 | 5.860 |
Why?
|
| Methotrexate | 15 | 2015 | 38 | 4.100 |
Why?
|
| Clinical Trials as Topic | 19 | 2015 | 216 | 3.360 |
Why?
|
| Joints | 17 | 2014 | 69 | 3.210 |
Why?
|
| Pain Measurement | 27 | 2019 | 484 | 3.120 |
Why?
|
| Humans | 171 | 2022 | 27125 | 3.100 |
Why?
|
| Osteoarthritis | 7 | 2019 | 330 | 2.780 |
Why?
|
| Glucocorticoids | 8 | 2020 | 68 | 2.650 |
Why?
|
| Fibromyalgia | 7 | 2019 | 30 | 2.410 |
Why?
|
| Checklist | 9 | 2021 | 33 | 2.100 |
Why?
|
| Remission Induction | 15 | 2016 | 90 | 1.960 |
Why?
|
| Prednisone | 6 | 2014 | 66 | 1.880 |
Why?
|
| Predictive Value of Tests | 20 | 2021 | 478 | 1.820 |
Why?
|
| Self Report | 10 | 2019 | 223 | 1.700 |
Why?
|
| Pain | 11 | 2017 | 412 | 1.650 |
Why?
|
| Prognosis | 20 | 2018 | 804 | 1.590 |
Why?
|
| Treatment Outcome | 32 | 2018 | 3525 | 1.520 |
Why?
|
| Medical History Taking | 5 | 2012 | 31 | 1.480 |
Why?
|
| Spondylitis, Ankylosing | 4 | 2022 | 20 | 1.470 |
Why?
|
| Physical Examination | 7 | 2013 | 116 | 1.340 |
Why?
|
| Middle Aged | 54 | 2021 | 9012 | 1.330 |
Why?
|
| Male | 60 | 2021 | 14801 | 1.220 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 178 | 1.210 |
Why?
|
| Female | 60 | 2021 | 15249 | 1.210 |
Why?
|
| Blood Sedimentation | 10 | 2014 | 53 | 1.200 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2013 | 77 | 1.190 |
Why?
|
| Physicians | 4 | 2015 | 124 | 1.160 |
Why?
|
| Office Visits | 4 | 2012 | 11 | 1.150 |
Why?
|
| Adult | 39 | 2021 | 7901 | 1.140 |
Why?
|
| Telemedicine | 3 | 2022 | 96 | 1.090 |
Why?
|
| Time Factors | 17 | 2019 | 1438 | 1.080 |
Why?
|
| Biological Products | 5 | 2013 | 43 | 1.070 |
Why?
|
| Medical Informatics | 2 | 2016 | 10 | 1.050 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 132 | 1.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2010 | 190 | 1.020 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 2015 | 190 | 0.980 |
Why?
|
| Depression | 2 | 2021 | 444 | 0.960 |
Why?
|
| Aged | 35 | 2021 | 9070 | 0.960 |
Why?
|
| Physician-Patient Relations | 5 | 2015 | 41 | 0.940 |
Why?
|
| Electronic Health Records | 3 | 2016 | 74 | 0.930 |
Why?
|
| Quality Improvement | 3 | 2017 | 137 | 0.930 |
Why?
|
| Reproducibility of Results | 11 | 2021 | 672 | 0.920 |
Why?
|
| Biomarkers | 7 | 2017 | 559 | 0.920 |
Why?
|
| Rheumatoid Factor | 3 | 2016 | 5 | 0.920 |
Why?
|
| Research Design | 4 | 2015 | 186 | 0.900 |
Why?
|
| Immunosuppressive Agents | 3 | 2015 | 120 | 0.900 |
Why?
|
| Cost of Illness | 3 | 2019 | 50 | 0.890 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 31 | 0.870 |
Why?
|
| Patient Participation | 2 | 2014 | 46 | 0.850 |
Why?
|
| Arthritis, Psoriatic | 4 | 2018 | 14 | 0.830 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 9 | 0.800 |
Why?
|
| C-Reactive Protein | 8 | 2022 | 96 | 0.800 |
Why?
|
| Internet | 2 | 2014 | 91 | 0.780 |
Why?
|
| Evidence-Based Medicine | 6 | 2015 | 161 | 0.770 |
Why?
|
| Inflammation | 4 | 2017 | 274 | 0.730 |
Why?
|
| Spondylarthritis | 1 | 2021 | 3 | 0.720 |
Why?
|
| Symptom Assessment | 1 | 2021 | 19 | 0.710 |
Why?
|
| Patient Health Questionnaire | 1 | 2021 | 12 | 0.700 |
Why?
|
| Activities of Daily Living | 11 | 2010 | 596 | 0.700 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 39 | 0.700 |
Why?
|
| Visual Analog Scale | 2 | 2017 | 84 | 0.680 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 320 | 0.670 |
Why?
|
| Fatigue | 4 | 2016 | 58 | 0.670 |
Why?
|
| Databases, Factual | 7 | 2016 | 350 | 0.670 |
Why?
|
| Ambulatory Care | 2 | 2013 | 69 | 0.660 |
Why?
|
| Health Impact Assessment | 1 | 2019 | 4 | 0.640 |
Why?
|
| Arthrography | 3 | 2009 | 29 | 0.640 |
Why?
|
| Physician's Role | 1 | 2019 | 15 | 0.620 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 28 | 0.610 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 510 | 0.600 |
Why?
|
| Chronic Disease | 6 | 2019 | 422 | 0.600 |
Why?
|
| Endpoint Determination | 6 | 2015 | 22 | 0.590 |
Why?
|
| Patient Care Planning | 3 | 2017 | 39 | 0.590 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 77 | 0.580 |
Why?
|
| Drug Therapy, Combination | 7 | 2013 | 168 | 0.580 |
Why?
|
| Medical Records | 3 | 2014 | 33 | 0.570 |
Why?
|
| Data Collection | 7 | 2011 | 90 | 0.560 |
Why?
|
| Peptides, Cyclic | 4 | 2010 | 9 | 0.560 |
Why?
|
| Patients | 2 | 2010 | 33 | 0.560 |
Why?
|
| Health Surveys | 3 | 2012 | 88 | 0.550 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2016 | 1 | 0.520 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 14 | 0.510 |
Why?
|
| Quality of Life | 4 | 2016 | 627 | 0.500 |
Why?
|
| Patient Care | 4 | 2014 | 31 | 0.500 |
Why?
|
| Drug Monitoring | 3 | 2009 | 11 | 0.490 |
Why?
|
| Communication | 3 | 2013 | 106 | 0.490 |
Why?
|
| Mortality, Premature | 1 | 2015 | 6 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2007 | 291 | 0.480 |
Why?
|
| Models, Theoretical | 2 | 2019 | 84 | 0.470 |
Why?
|
| Diabetes Mellitus | 3 | 2012 | 129 | 0.460 |
Why?
|
| Chronobiology Disorders | 1 | 2014 | 14 | 0.450 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 33 | 0.450 |
Why?
|
| Hypertension | 3 | 2012 | 193 | 0.450 |
Why?
|
| Self-Assessment | 3 | 2009 | 29 | 0.440 |
Why?
|
| Patient Selection | 3 | 2009 | 197 | 0.440 |
Why?
|
| Comorbidity | 4 | 2021 | 488 | 0.440 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 22 | 0.430 |
Why?
|
| Private Practice | 2 | 2004 | 6 | 0.430 |
Why?
|
| Coronary Artery Disease | 9 | 2010 | 132 | 0.430 |
Why?
|
| Retrospective Studies | 8 | 2019 | 3542 | 0.420 |
Why?
|
| Clinical Protocols | 3 | 2013 | 58 | 0.410 |
Why?
|
| Exercise | 2 | 2016 | 452 | 0.400 |
Why?
|
| Quality of Health Care | 3 | 2009 | 102 | 0.400 |
Why?
|
| Cross-Sectional Studies | 9 | 2016 | 902 | 0.390 |
Why?
|
| Education, Distance | 2 | 2022 | 16 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 331 | 0.380 |
Why?
|
| Immunoconjugates | 1 | 2011 | 7 | 0.380 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2011 | 1 | 0.370 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 236 | 0.370 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 42 | 0.360 |
Why?
|
| Biomedical Research | 3 | 2007 | 59 | 0.360 |
Why?
|
| Referral and Consultation | 1 | 2012 | 88 | 0.360 |
Why?
|
| Disease Progression | 5 | 2016 | 672 | 0.350 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 37 | 0.350 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 54 | 0.340 |
Why?
|
| Adalimumab | 4 | 2017 | 16 | 0.340 |
Why?
|
| Longitudinal Studies | 6 | 2014 | 1369 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 29 | 0.340 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 11 | 0.330 |
Why?
|
| Immunologic Tests | 1 | 2009 | 3 | 0.330 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2009 | 3 | 0.330 |
Why?
|
| Diagnosis-Related Groups | 1 | 2009 | 8 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2010 | 28 | 0.330 |
Why?
|
| Quality Control | 1 | 2009 | 27 | 0.330 |
Why?
|
| Decision Support Techniques | 2 | 2010 | 47 | 0.320 |
Why?
|
| Immunologic Factors | 1 | 2009 | 29 | 0.320 |
Why?
|
| Global Health | 2 | 2010 | 36 | 0.310 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 479 | 0.310 |
Why?
|
| Educational Status | 3 | 2010 | 289 | 0.310 |
Why?
|
| Autoantibodies | 1 | 2009 | 82 | 0.310 |
Why?
|
| United States | 11 | 2022 | 2054 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2009 | 175 | 0.300 |
Why?
|
| Review Literature as Topic | 1 | 2008 | 10 | 0.300 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 33 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 110 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2011 | 87 | 0.280 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 110 | 0.270 |
Why?
|
| Terminology as Topic | 7 | 2011 | 32 | 0.270 |
Why?
|
| Prednisolone | 1 | 2007 | 8 | 0.270 |
Why?
|
| Professional Practice | 1 | 2006 | 5 | 0.270 |
Why?
|
| Case Management | 1 | 2006 | 8 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 30 | 0.270 |
Why?
|
| Social Class | 3 | 2019 | 64 | 0.260 |
Why?
|
| Calcinosis | 8 | 2010 | 44 | 0.250 |
Why?
|
| Clinical Medicine | 1 | 2005 | 1 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2006 | 17 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 2 | 2007 | 260 | 0.250 |
Why?
|
| Isoxazoles | 1 | 2005 | 5 | 0.240 |
Why?
|
| Diclofenac | 1 | 2005 | 3 | 0.240 |
Why?
|
| Misoprostol | 1 | 2005 | 5 | 0.240 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 17 | 0.240 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 66 | 0.230 |
Why?
|
| Acetaminophen | 1 | 2005 | 24 | 0.230 |
Why?
|
| Radiography | 5 | 2012 | 616 | 0.230 |
Why?
|
| Abatacept | 2 | 2017 | 6 | 0.230 |
Why?
|
| Osteoarthritis, Hip | 1 | 2005 | 105 | 0.220 |
Why?
|
| Recovery of Function | 1 | 2005 | 297 | 0.210 |
Why?
|
| Risk Factors | 7 | 2019 | 2331 | 0.210 |
Why?
|
| Forecasting | 2 | 2016 | 92 | 0.190 |
Why?
|
| Early Diagnosis | 5 | 2010 | 58 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 303 | 0.180 |
Why?
|
| Infliximab | 3 | 2006 | 17 | 0.180 |
Why?
|
| Prospective Studies | 2 | 2018 | 1774 | 0.180 |
Why?
|
| Documentation | 2 | 2012 | 23 | 0.180 |
Why?
|
| Gout | 2 | 2013 | 5 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 146 | 0.170 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 372 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 76 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 161 | 0.170 |
Why?
|
| Ontario | 1 | 2019 | 16 | 0.160 |
Why?
|
| Prevalence | 4 | 2016 | 456 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 331 | 0.160 |
Why?
|
| International Cooperation | 5 | 2010 | 15 | 0.150 |
Why?
|
| Sickness Impact Profile | 1 | 2018 | 9 | 0.150 |
Why?
|
| Finland | 2 | 2009 | 4 | 0.150 |
Why?
|
| Pain Management | 2 | 2009 | 143 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1802 | 0.140 |
Why?
|
| Observer Variation | 2 | 2008 | 96 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 19 | 0.130 |
Why?
|
| Cell Phone | 1 | 2016 | 7 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 30 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 24 | 0.130 |
Why?
|
| Psychometrics | 2 | 2009 | 218 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2009 | 1901 | 0.130 |
Why?
|
| Health Services Research | 1 | 2016 | 38 | 0.130 |
Why?
|
| Mobile Applications | 1 | 2016 | 29 | 0.130 |
Why?
|
| France | 1 | 2016 | 13 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2010 | 4828 | 0.120 |
Why?
|
| Republic of Korea | 1 | 2015 | 6 | 0.120 |
Why?
|
| Societies, Medical | 4 | 2010 | 123 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2007 | 350 | 0.110 |
Why?
|
| Registries | 1 | 2015 | 193 | 0.110 |
Why?
|
| Europe | 5 | 2011 | 57 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2009 | 589 | 0.110 |
Why?
|
| Spondylarthropathies | 1 | 2013 | 4 | 0.110 |
Why?
|
| Tennessee | 1 | 2013 | 6 | 0.100 |
Why?
|
| Chicago | 1 | 2016 | 947 | 0.100 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 3 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 256 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 309 | 0.100 |
Why?
|
| Pulmonary Fibrosis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Arthritis | 1 | 2013 | 52 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2010 | 129 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 23 | 0.100 |
Why?
|
| Lymphoma | 1 | 2012 | 36 | 0.100 |
Why?
|
| Arthralgia | 1 | 2014 | 132 | 0.100 |
Why?
|
| Workflow | 1 | 2012 | 8 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2012 | 59 | 0.100 |
Why?
|
| Certolizumab Pegol | 1 | 2011 | 1 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 34 | 0.090 |
Why?
|
| Heart Failure | 1 | 2012 | 149 | 0.090 |
Why?
|
| Lipoproteins | 1 | 2010 | 10 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 6 | 0.090 |
Why?
|
| Connective Tissue Diseases | 1 | 2010 | 9 | 0.080 |
Why?
|
| Rituximab | 1 | 2010 | 47 | 0.080 |
Why?
|
| Time Management | 1 | 2010 | 4 | 0.080 |
Why?
|
| MMPI | 1 | 2009 | 3 | 0.080 |
Why?
|
| Dyspnea | 1 | 2010 | 42 | 0.080 |
Why?
|
| Employment | 1 | 2010 | 38 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2009 | 73 | 0.080 |
Why?
|
| Hand Joints | 1 | 2009 | 3 | 0.080 |
Why?
|
| Foot Joints | 1 | 2009 | 4 | 0.080 |
Why?
|
| Adipokines | 1 | 2009 | 7 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 67 | 0.080 |
Why?
|
| Mass Screening | 1 | 2010 | 173 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 347 | 0.080 |
Why?
|
| Health Literacy | 1 | 2010 | 108 | 0.080 |
Why?
|
| Mortality | 1 | 2009 | 93 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 9 | 0.080 |
Why?
|
| Drug Industry | 1 | 2008 | 6 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Disclosure | 1 | 2008 | 13 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 76 | 0.070 |
Why?
|
| Disabled Persons | 1 | 2010 | 122 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2008 | 50 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 6 | 0.070 |
Why?
|
| Familial Mediterranean Fever | 1 | 2007 | 1 | 0.070 |
Why?
|
| Behcet Syndrome | 1 | 2007 | 4 | 0.070 |
Why?
|
| Scleroderma, Localized | 1 | 2007 | 5 | 0.070 |
Why?
|
| Osteoprotegerin | 1 | 2007 | 5 | 0.070 |
Why?
|
| Vasculitis | 1 | 2007 | 27 | 0.070 |
Why?
|
| Forms and Records Control | 1 | 2007 | 9 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 27 | 0.070 |
Why?
|
| Etanercept | 1 | 2006 | 21 | 0.070 |
Why?
|
| Antibodies | 1 | 2007 | 46 | 0.070 |
Why?
|
| Adolescent | 2 | 2003 | 2177 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2006 | 47 | 0.070 |
Why?
|
| Animals | 1 | 2014 | 3625 | 0.070 |
Why?
|
| Acute-Phase Reaction | 3 | 2010 | 4 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2009 | 210 | 0.070 |
Why?
|
| Incidence | 1 | 2009 | 762 | 0.070 |
Why?
|
| Cause of Death | 1 | 2007 | 65 | 0.070 |
Why?
|
| North America | 3 | 2010 | 39 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 80 | 0.060 |
Why?
|
| Synovitis | 3 | 2010 | 22 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 127 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 58 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2007 | 54 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2007 | 84 | 0.060 |
Why?
|
| Sex Factors | 3 | 2015 | 466 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 344 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 321 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2007 | 222 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 159 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 65 | 0.060 |
Why?
|
| Self-Help Devices | 1 | 2004 | 5 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 2009 | 75 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 324 | 0.060 |
Why?
|
| Postal Service | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sleep Wake Disorders | 1 | 2005 | 122 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2005 | 407 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 415 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2003 | 3 | 0.050 |
Why?
|
| Rheumatologists | 1 | 2022 | 15 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 43 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 1104 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 397 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 110 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 114 | 0.040 |
Why?
|
| England | 1 | 2020 | 16 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 39 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 240 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 64 | 0.040 |
Why?
|
| Algorithms | 2 | 2010 | 351 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 141 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 18 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 56 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 72 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 246 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2008 | 258 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2009 | 461 | 0.030 |
Why?
|
| Smoking | 2 | 2008 | 183 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 628 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 10 | 0.030 |
Why?
|
| Bias | 1 | 2015 | 30 | 0.030 |
Why?
|
| Physicians, Women | 1 | 2015 | 15 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 667 | 0.030 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2010 | 4 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 5 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2010 | 1 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 8 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 23 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 37 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 50 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 25 | 0.020 |
Why?
|
| Occupational Medicine | 1 | 2010 | 1 | 0.020 |
Why?
|
| Insurance, Disability | 1 | 2010 | 1 | 0.020 |
Why?
|
| Work Capacity Evaluation | 1 | 2010 | 8 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 91 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 73 | 0.020 |
Why?
|
| Self Care | 1 | 2010 | 89 | 0.020 |
Why?
|
| Serum Amyloid A Protein | 1 | 2009 | 1 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2009 | 1 | 0.020 |
Why?
|
| E-Selectin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Peroxidase | 1 | 2009 | 15 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Resistin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2009 | 1 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 95 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 10 | 0.020 |
Why?
|
| Leptin | 1 | 2009 | 21 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 78 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 100 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2008 | 49 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 119 | 0.020 |
Why?
|
| Lipids | 1 | 2008 | 50 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 18 | 0.020 |
Why?
|
| Internationality | 1 | 2008 | 20 | 0.020 |
Why?
|
| Insulin | 1 | 2008 | 91 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 277 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2008 | 108 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2008 | 195 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 22 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 77 | 0.020 |
Why?
|
| Life Style | 1 | 2008 | 186 | 0.020 |
Why?
|
| Obesity | 1 | 2009 | 309 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 775 | 0.020 |
Why?
|
| Canada | 1 | 2005 | 46 | 0.020 |
Why?
|